Development of an Effective Palladium Removal Process for VEGF Oncology Candidate AG13736 and a Simple, Efficient Screening Technique for Scavenger Reagent Identification

Citations Over TimeTop 10% of 2008 papers

Abstract

AG13736 (Axitinib), an inhibitor of vascular endothelial growth factor (VEGF) under investigation as an oncology drug, is currently manufactured via a three-step process that utilizes two palladium-mediated cross-couplings. Historically, removal of residual heavy metals from the active pharmaceutical ingredient has been a persistent issue. The development of a much improved process for palladium removal and a useful screening technique developed to rapidly identify the most efficient reagents for this purpose are outlined. The performance of the new endgame process in pilot-plant scale-up is also discussed.

Related Papers

• → Serum vascular endothelial growth factor (VEGF), soluble VEGF receptor-1 (sVEGFR-1) and sVEGFR-2 in systemic sclerosis patients: Relation to clinical manifestations and capillaroscopy findings(2016)19 cited
• → Expression of total vascular endothelial growth factor (VEGF) and inhibitory isoforms of VEGF in head and neck squamous cell carcinoma(2012)
• → Cross-talk between Airway and Vascular Remodeling.(2011)
• → Περιεγχειρητική διακύμανση του αυξητικού παράγοντα αγγειακού ενδοθηλίου (vascular endothelial growth factor/VEGF) σε ασθενείς με καρκίνο παχέος εντέρου και ασθενείς με καρκίνο μαστού(2013)